<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:georss="http://www.georss.org/georss" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" > <channel> <title> Comments on: Pfizer Biocon signals the end for biosimilars? Hardly… </title> <atom:link href="https://lacertabio.com/pfizer-biocon-signals-the-end-for-biosimilars-hardly/feed/" rel="self" type="application/rss+xml" /> <link>https://lacertabio.com/pfizer-biocon-signals-the-end-for-biosimilars-hardly/</link> <description>Lacerta Bio is a business development consultancy specializing in identifying, assessing, negotiating, and closing licensing and partnership opportunities for the pharmaceutical, biotechnology, and drug delivery industries.</description> <lastBuildDate>Thu, 15 Mar 2012 14:37:49 +0000</lastBuildDate> <sy:updatePeriod> hourly </sy:updatePeriod> <sy:updateFrequency> 1 </sy:updateFrequency> <generator>https://wordpress.org/?v=6.7.2</generator> </channel> </rss>